Award
National Institute on Aging 1R01AG092949-01
FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants.
Recipient
National Institute on Aging (NIA)
Award Amount
$5,308,961.00
Ceiling
$5,308,961.00
Awarded
July 23, 2025
Identifier
1R01AG092949-01
This NIH/NIA funded project supports a Phase 1 clinical trial to evaluate the safety and immune response of a preventive tau vaccine for Alzheimer's disease in cognitively unimpaired individuals, with a total funding of approximately $5.3 million over five years.
Description
A Phase 1 safety and immunogenicity trial of a tau vaccine for Alzheimer's disease targeting preclinical AD individuals, funded by the NIH/NIA using the MultiTEP vaccine platform.